{"id":37625,"date":"2025-07-21T14:42:13","date_gmt":"2025-07-21T06:42:13","guid":{"rendered":"https:\/\/flcube.com\/?p=37625"},"modified":"2025-07-21T14:42:14","modified_gmt":"2025-07-21T06:42:14","slug":"sarepta-therapeutics-announces-500-employee-layoffs-after-fda-elevidys-trial-suspension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37625","title":{"rendered":"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">US-based Sarepta Therapeutics, a subsidiary of Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>), announced the layoff of approximately 500 employees\u2014about 36% of its workforce\u2014and a restructuring of its R&amp;D pipeline. The company will now focus on its siRNA platform for developing therapies in neurodegenerative and other disease areas. This decision follows the FDA&#8217;s suspension of clinical trials related to Sarepta&#8217;s gene therapy product, Elevidys.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA actions<\/strong><br>According to an FDA statement, three non-ambulatory patients with Duchenne muscular dystrophy (DMD) died after receiving Sarepta&#8217;s gene therapies based on its AAVrh74 platform. One of these deaths was linked to Elevidys and involved acute liver failure. Consequently, the FDA has ordered Sarepta to suspend the distribution of Elevidys and all clinical trials involving the AAVrh74 platform. The FDA has also revoked the platform&#8217;s designation as a &#8220;platform technology.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Impact on Elevidys<\/strong><br>Elevidys received accelerated approval from the FDA in 2023 for non-ambulatory DMD patients. In 2024, the approved indication was expanded to include ambulatory patients aged four years and older. In response to the safety events, the FDA has required Sarepta to update its product labeling with a boxed warning and to limit the approved indication to ambulatory DMD patients aged four and above.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Future Direction<\/strong><br>While Sarepta will continue advancing SRP-9003 (for LGMD-2E), several other programs, including most of its gene therapy candidates for limb-girdle muscular dystrophy (LGMD), will be paused. Sarepta stated that these measures aim to reduce operating costs, optimize resource allocation, and realign its R&amp;D strategy amid changing regulatory conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37626,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[867,24,147,2027],"class_list":["post-37625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nasdaq-sny","tag-rare-orphan-disease-drugs","tag-sanofi","tag-sarepta-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500 employees\u2014about 36% of its workforce\u2014and a restructuring of its R&amp;D pipeline. The company will now focus on its siRNA platform for developing therapies in neurodegenerative and other disease areas. This decision follows the FDA&#039;s suspension of clinical trials related to Sarepta&#039;s gene therapy product, Elevidys.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37625\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension\" \/>\n<meta property=\"og:description\" content=\"US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500 employees\u2014about 36% of its workforce\u2014and a restructuring of its R&amp;D pipeline. The company will now focus on its siRNA platform for developing therapies in neurodegenerative and other disease areas. This decision follows the FDA&#039;s suspension of clinical trials related to Sarepta&#039;s gene therapy product, Elevidys.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37625\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-21T06:42:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-21T06:42:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension\",\"datePublished\":\"2025-07-21T06:42:13+00:00\",\"dateModified\":\"2025-07-21T06:42:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625\"},\"wordCount\":268,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2102.webp\",\"keywords\":[\"NASDAQ: SNY\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\",\"Sarepta Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37625#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37625\",\"name\":\"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2102.webp\",\"datePublished\":\"2025-07-21T06:42:13+00:00\",\"dateModified\":\"2025-07-21T06:42:14+00:00\",\"description\":\"US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500 employees\u2014about 36% of its workforce\u2014and a restructuring of its R&D pipeline. The company will now focus on its siRNA platform for developing therapies in neurodegenerative and other disease areas. This decision follows the FDA's suspension of clinical trials related to Sarepta's gene therapy product, Elevidys.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37625\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/2102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37625#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension - Insight, China&#039;s Pharmaceutical Industry","description":"US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500 employees\u2014about 36% of its workforce\u2014and a restructuring of its R&D pipeline. The company will now focus on its siRNA platform for developing therapies in neurodegenerative and other disease areas. This decision follows the FDA's suspension of clinical trials related to Sarepta's gene therapy product, Elevidys.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37625","og_locale":"en_US","og_type":"article","og_title":"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension","og_description":"US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500 employees\u2014about 36% of its workforce\u2014and a restructuring of its R&D pipeline. The company will now focus on its siRNA platform for developing therapies in neurodegenerative and other disease areas. This decision follows the FDA's suspension of clinical trials related to Sarepta's gene therapy product, Elevidys.","og_url":"https:\/\/flcube.com\/?p=37625","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-21T06:42:13+00:00","article_modified_time":"2025-07-21T06:42:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37625#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37625"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension","datePublished":"2025-07-21T06:42:13+00:00","dateModified":"2025-07-21T06:42:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37625"},"wordCount":268,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37625#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2102.webp","keywords":["NASDAQ: SNY","Rare \/ orphan disease drugs","Sanofi","Sarepta Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37625#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37625","url":"https:\/\/flcube.com\/?p=37625","name":"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37625#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37625#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2102.webp","datePublished":"2025-07-21T06:42:13+00:00","dateModified":"2025-07-21T06:42:14+00:00","description":"US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500 employees\u2014about 36% of its workforce\u2014and a restructuring of its R&D pipeline. The company will now focus on its siRNA platform for developing therapies in neurodegenerative and other disease areas. This decision follows the FDA's suspension of clinical trials related to Sarepta's gene therapy product, Elevidys.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37625#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37625"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37625#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2102.webp","width":1080,"height":608,"caption":"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37625#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37625"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37625\/revisions"}],"predecessor-version":[{"id":37627,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37625\/revisions\/37627"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37626"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}